YS Biopharma Co Ltd
NASDAQ:LSB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
YS Biopharma Co Ltd
Additional Paid In Capital
YS Biopharma Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
YS Biopharma Co Ltd
NASDAQ:LSB
|
Additional Paid In Capital
¥3B
|
CAGR 3-Years
54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Additional Paid In Capital
¥90.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Additional Paid In Capital
¥6.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
YS Biopharma Co Ltd
Glance View
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
See Also
What is YS Biopharma Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
3B
CNY
Based on the financial report for Mar 31, 2025, YS Biopharma Co Ltd's Additional Paid In Capital amounts to 3B CNY.
What is YS Biopharma Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
54%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for YS Biopharma Co Ltd have been 54% over the past three years .
